Analyst Profile

Followed by 2,769 followers
.
Mayank Mamtani

Mayank Mamtani

B.Riley Financial
Wall Street Analyst
#8,080 out of 8,160 Wall Street Analysts
#24,010 out of 24,427 experts

Success Rate

22%
77 out of 351 transactions made a profit

Average Return

-30.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Mayank Mamtani's trades since 2020 and holding each position for 1 Year would result in 21.94% of your transactions generating a profit, with an average return of -30.0% per rating.

Stock Rating Distribution

954Ratings
91.51% Buy
7.55% Hold
0.94% Sell
Distribution of Mayank Mamtani's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Biovie Inc.
(BIVI)
Rating:Buy
Date:Jul 28, 2022 - Today
Return:+207.70%
The most profitable rating made by Mayank Mamtani

Mayank Mamtani's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
ARQL
Arqule
Jan 17, 2020
Hold
Assigned
3Ratings
0.00%
MDCO
Medicines Co
Jan 17, 2020
Hold
Assigned
16Ratings
0.00%
Genfit
May 12, 2020
Hold
Downgraded
4Ratings
0.00%
Sutro Biopharma
May 12, 2020
Hold
Downgraded
1Ratings
0.00%
Galmed Pharmaceuticals
Oct 06, 2020
Hold
Assigned
11Ratings
0.00%
Genfit SA
Oct 06, 2020
Hold
Assigned
18Ratings
0.00%
IMV
Oct 06, 2020
Hold
Assigned
18Ratings
0.00%
F-star Therapeutics
Oct 06, 2020
Hold
Assigned
9Ratings
0.00%
Acasti Pharma
Oct 06, 2020
Hold
Assigned
10Ratings
0.00%
Galectin Therapeutics
Oct 06, 2020
Hold
Assigned
7Ratings
0.00%
List of latest recommendations made by Mayank Mamtani. Click to expand and see Mayank Mamtani's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >